Ferner Rosalie E, Gutmann David H
Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, UK.
Handb Clin Neurol. 2013;115:939-55. doi: 10.1016/B978-0-444-52902-2.00053-9.
Neurofibromatosis 1 (NF1) is an inherited neurocutaneous disease that has a major impact on the nervous system, eye, skin, and bone. Individuals with NF1 have a predisposition to benign and malignant tumor formation and the hallmark lesion is the neurofibroma, a benign peripheral nerve sheath tumor. The gene for NF1 was cloned on chromosome 17q11.2 and neurofibromin, the NF1 protein, controls cell growth and proliferation by regulating the proto-oncogene Ras and cyclic adenosine monophosphate (AMP). Advances in molecular biology and mouse models of disease have enhanced our understanding of the pathogenesis of NF1 complications and facilitated targeted therapy. Progress has been made in developing robust clinical and radiological outcome measures and clinical trials are underway for children with learning difficulties and for individuals with symptomatic plexiform neurofibromas.
神经纤维瘤病1型(NF1)是一种遗传性神经皮肤疾病,对神经系统、眼睛、皮肤和骨骼有重大影响。患有NF1的个体易发生良性和恶性肿瘤,标志性病变是神经纤维瘤,一种良性周围神经鞘瘤。NF1基因定位于17号染色体q11.2区域,神经纤维瘤蛋白(NF1蛋白)通过调节原癌基因Ras和环磷酸腺苷(AMP)来控制细胞生长和增殖。分子生物学和疾病小鼠模型的进展加深了我们对NF1并发症发病机制的理解,并促进了靶向治疗。在制定可靠的临床和放射学结局指标方面取得了进展,针对有学习困难的儿童和有症状的丛状神经纤维瘤患者的临床试验正在进行。